Micafungin

Micafungin, is an antifungal drug, Inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls which is not present in mammalian cells. It does this by inhibiting beta-1,3-D-glucan synthase.

Indications

Micafungin is Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis. It is Indicated for the prophylaxis of Candida infections in patients undergoing -Micafungin is indicated for the treatment of invasive candidiasis, esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. -Hematopoietic stem cell transplantation.

Dosage

-The dosage of micafungin varies based on the specific infection being treated. It is typically administered intravenously by a healthcare professional. -Intravenous Infusion; Usual Adult Dose for Esophageal Candidiasis 150 mg IV once a day (10 to 30 days) -Usual Adult Dose for Fungal Infection Prophylaxis 50 mg IV once a day (6 to 51 days) -Usual Adult Dose for Candidemia 100 mg IV once a day (10 to 47 days) -Usual Pediatric Dose for Esophageal Candidiasis 4 months or older: Weight 30 kg or less: 3 mg/kg IV once a day Weight greater than 30 kg: 2.5 mg/kg IV once a day Maximum dose: 150 mg/day -Usual Pediatric Dose for Fungal Infection Prophylaxis 4 months or older: 1 mg/kg IV once a day Maximum dose: 50 mg/day -Usual Pediatric Dose for Candidemia Younger than 4 months: 4 mg/kg IV once a day 4 months or older: 2 mg/kg IV once a day -Maximum dose: 100 mg/day

Contra-Indications

-Micafungin is contraindicated in individuals with known hypersensitivity to the drug or any of its components. -Hypersensitivity

Special Precautions

-Patients with liver dysfunction should be monitored closely during micafungin therapy. Caution is advised in patients with co-existing hepatic impairment. Paediatric: Not to give in less than 4 month old child. Pregnancy: Data not sufficient. Lactation: Data not sufficient. Elderly: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

Side Effects

-Common side effects may include diarrhea, nausea, vomiting, headache, fever, and rash. Serious but rare side effects may include liver problems and allergic reactions. Immediate medical attention is required if severe or persistent side effects occur. -Black, tarry, stools, cough, decreased frequency or amount of urine, fast pounding, or irregular heartbeat or pulse, fever or chills, increased thirst, loss of appetite, lower back or side pain, nausea or vomiting, painful or difficult urination, pale skin, pinpoint red spots on the skin, swelling of the face, fingers, or lower legs, trouble breathing, ulcers, sores, or white spots in the mouth, unusual bleeding or bruising, unusual tiredness or weakness, weight gain.

Drug Interactions

-Co-administration with drugs that are metabolized by CYP450 enzymes may lead to potential interactions. It is essential to inform healthcare providers of all medications, including over-the-counter drugs and herbal supplements, being taken concurrently. -Acenocoumarol, Dicoumarol, Entacapone, Fluindione, Opicapone, Opicapone, Sirolimus, Temsirolimus, Testosterone propionate, Tolcapone, Warfarin